This site is intended for health professionals only

Nasal spray relieves cancer pain


A new nasal spray to treat breakthrough cancer pain has achieved its primary efficacy endpoint in a pivotal phase III clinical trial, pharmaceutical firm Archimedes Pharma has reported.

NasalFent, the company’s fentanyl citrate nasal spray, showed a greater reduction in pain in patients with breakthrough cancer pain.

Such pain affects up to 95% of all cancer patients and is rapid in onset, often reaching maximum intensity within five minutes and lasting between 30 minutes and an hour.

NasalFent showed a highly-statistically significant improvement in summary of pain intensity difference at 30 minutes (SPID30) compared with placebo.

Patients also reported statistically-significant differences in pain scores with NasalFent compared to placebo within five minutes of dosing. Archimedes Pharma said that NasalFent is the first product to have demonstrated, in a robust large scale phase III programme, onset of pain relief as early as five minutes.

The improvement in pain was maintained for 60 minutes after dosing with statistically-significant results at all measured time points.

Richard de Souza, chief executive of Archimedes, said: “We are pleased with the study results which position NasalFent, the first real intranasal form of fentanyl, as a product that redefines the standard of care for patients suffering with breakthrough cancer pain.”

Copyright PA Business 2008

Archimedes Pharma

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine